Search
Kentucky Paid Clinical Trials
A listing of 1061 clinical trials in Kentucky actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
493 - 504 of 1061
Kentucky is currently home to 1061 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts;... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Loupe-Based Intraoperative Fluorescence Imaging
Recruiting
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections.
This study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/03/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting
The primary objective of the study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs).
Secondary Objectives:
To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure
To evaluate the safety and tolerability of Fp/A BS
The duration for each particip... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/02/2025
Locations: Teva Investigational Site 15627, Lexington, Kentucky
Conditions: Asthma
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
07/02/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: FSGS
Blood Flow Restriction Training After Patellar INStability
Recruiting
This research study is designed to allow health care professionals and researchers to answer many questions about whether a new type of physical therapy called blood flow restriction training (called BFRT) will improve recovery for those with patellar instability.
Gender:
ALL
Ages:
Between 14 years and 40 years
Trial Updated:
07/02/2025
Locations: UK Healthcare at Turfland, Lexington, Kentucky
Conditions: Patellar Dislocation, Knee Injuries, Leg Injury, Wounds and Injuries
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Brain Metastases
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Saint Joseph Hospital, Lexington, Kentucky
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Recruiting
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:
* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?
* How do risk markers of disease change over the study in the study participant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/01/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Type 1 Diabetes
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Lexington, Kentucky
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer